• About
• Links
• Contact
• Sitemap
• 

Angina Pectoris - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

The report is an essential source of information and analysis on the global angina pectoris market. The report identifies the key trends shaping and driving the global angina pectoris market, a key segment within the pharma industry. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global angina pectoris sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.

Scope

The scope of the report includes:

Annualized global angina pectoris market revenue data from 2001 to 2009, forecast forward 7 years to 2016.

Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.

Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action includes gene therapy, combinational therapies, nitric oxide targettors, beta-1 adrenergic receptor antagonists, stem cell therapy, enzyme inhibitors, immunologic drugs, coagulation factor Xa inhibitors, adenosine A1 agonists, anticoagulants and calcium/potassium and sodium channel blockers.

Analysis of the current and future market competition in the global angina pectoris market. The key market players covered are Solvay Pharmaceuticals, Cardium Therapeutics, Inc., Bayer Healthcare AG., Atherogenics, Inc., Cytokinetics, Inc, Arca Biopharma, Inc., Anthera Pharmaceuticals, Inc, Lacer S.A and Circ Pharma.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with angina pectoris

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global angina pectoris market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global angina pectoris market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next big thing in the global angina pectoris market landscape? – Identify, understand and capitalize.

Table of Contents

1 Table of contents 3

• 1.1 List of Tables 5
• 1.2 List of Figures 5

2 Angina Pectoris Market: Market Characterization 6

• 2.1 Overview 6
• 2.2 Angina Pectoris Market Size 6
• 2.3 Angina Pectoris Market Forecast and CAGR 6
• 2.4 Drivers and Barriers for the Angina Pectoris Market 7
  • 2.4.1 Drivers for the Angina Pectoris Market 8
  • 2.4.2 Barriers for the Angina Pectoris Market 8
• 2.5 Opportunity and Unmet Need 8
• 2.6 Key Takeaway 10

3 Angina Pectoris Market: Competitive Assessment 11

• 3.1 Overview 11
• 3.2 Strategic Competitor Assessment 11
• 3.3 Major Therapies and Product Profiles for the Major Marketed Products in the Angina Pectoris Market 12
  • 3.3.1 Calcium Channel Blockers 12
  • 3.3.2 Nitrates 13
  • 3.3.3 Beta-adrenergic Blocking Agents (Beta Blockers) 14
  • 3.3.4 Angiotensin Converting Enzyme Inhibitor (ACE inhibitors) 14
  • 3.3.5 Statins 15
  • 3.3.6 Sodium Channel Current Inhibitor 16
  • 3.3.7 Selective If Channel Inhibitor 18
  • 3.3.8 Glycoprotein IIb/IIIa inhibitor 19
• 3.4 Key Takeaway 25

4 Angina Pectoris Market: Pipeline Assessment 26

• 4.1 Overview 26
• 4.2 Strategic Pipeline Assessment 26
  • 4.2.1 Technology Trends Analytic Framework 26
• 4.3 Angina Pectoris Therapeutics – Promising Drugs under Clinical Development 27
• 4.4 Molecule Profile for Promising Drugs under Clinical Development 29
  • 4.4.1 Generx (Alferminogene Tadenovec, Ad5FGF-4) 29
  • 4.4.2 Rivaroxaban (Xarelto, BAY 59-7939) 31
  • 4.4.3 Tedangin (Tedisamil Sesquifumurate, KC-8857, Pulzium) 33
  • 4.4.4 Fasudil (AT-877) 34
  • 4.4.5 AGI-1067 (Succinobucol) 35
  • 4.4.6 CK-1827452 (Omecamtiv mecarbil, CK-452) 36
  • 4.4.7 RNAPc2 (recombinant nematode anticoagulant protein c2) 37
  • 4.4.8 A-002 (Varespladib Methyl) 38
  • 4.4.9 LA419 (S-(6-Nitro-oxi-hexahydrofuro[3,2-b]furan-3-1-il)thioacetate]) 39
• 4.5 Angina Pectoris Therapeutics Market – Clinical Pipeline by Mechanism of Action 40
• 4.6 Angina Pectoris Pipeline – Pipeline by Clinical Phases of Development 41
  • 4.6.1 Angina Pectoris Therapeutics – Phase III Clinical Pipeline 41
  • 4.6.2 Angina Pectoris Therapeutics – Phase II Clinical Pipeline 42
  • 4.6.3 Angina Pectoris Therapeutics – Phase I Clinical Pipeline 43
  • 4.6.4 Angina Pectoris Therapeutics – Preclinical Pipeline 43
• 4.7 Discontinued / Suspended Drug for Angina Pectoris 44
• 4.8 Key Takeaway 45

5 Angina Pectoris Market: Implications for Future Market Competition 47

6 Angina Pectoris Market: Future Players in the Angina Pectoris Market 48

• 6.1 Introduction 48
• 6.2 Cardium Therapeutics, Inc. 48
  • 6.2.1 Overview 48
  • 6.2.2 Cardiovascular Disease Portfolio 49
  • 6.2.3 Angina Product Portfolio 49
• 6.3 Bayer Healthcare AG 51
  • 6.3.1 Overview 51
  • 6.3.2 Cardiovascular Disease Portfolio 52
  • 6.3.3 Angina Product Portfolio 52
• 6.4 Solvay Pharmaceuticals 53
  • 6.4.1 Overview 53
  • 6.4.2 Cardiovascular Disease Portfolio 54
  • 6.4.3 Angina Product Portfolio 54
• 6.5 Atherogenics, Inc. 55
  • 6.5.1 Overview 55
  • 6.5.2 Cardiovascular Disease Portfolio 56
  • 6.5.3 Angina Product Portfolio 56
• 6.6 Cytokinetics, Inc. 57
  • 6.6.1 Business Description 57
  • 6.6.2 Cardiovascular Disease Portfolio 58
  • 6.6.3 Angina Product Portfolio 58
• 6.7 ARCA Biopharma. Inc. 59
  • 6.7.1 Overview 59
  • 6.7.2 Cardiovascular Disease Portfolio 59
  • 6.7.3 Angina Product Portfolio 59
• 6.8 Anthera Pharmaceuticals, Inc. 61
  • 6.8.1 Overview 61
  • 6.8.2 Cardiovascular Disease Portfolio 61
  • 6.8.3 Angina Product Portfolio 61
• 6.9 Lacer S.A 62
  • 6.9.1 Business Description 62
  • 6.9.2 Cardiovascular Disease Portfolio 62
  • 6.9.3 Angina Product Portfolio 62
• 6.10 Circ Pharma 63
  • 6.10.1 Business Description 63
  • 6.10.2 Cardiovascular Disease Portfolio 64
  • 6.10.3 Angina Product Portfolio 64

7 Angina Pectoris Market: Appendix 65

• 7.1 Market Definitions 65
• 7.2 Abbreviations 65
  • 7.2.1 Coverage 67
  • 7.2.2 Secondary Research 67
  • 7.2.3 Forecasting 68
  • 7.2.4 Primary Research 70
  • 7.2.5 Expert Panels Validation 71
• 7.3 Contact Us 71
• 7.4 Disclaimer 71
• 7.5 Sources 71

1.1 List of Tables

• Table 1: Global Angina Pectoris Market Revenue ($bn), 2001-2009 7
• Table 2: Global Angina Pectoris Market Revenue ($bn), 2009-2016 7
• Table 3: Major Marketed Products Comparison in the Angina Pectoris Market, January 2010 24
• Table 4: Angina Pectoris Therapeutics – Most Promising Drugs Under Clinical Development, 2010 27
• Table 5: Angina Pectoris Therapeutics – Phase III Clinical Pipeline, 2010 41
• Table 6: Angina Pectoris Therapeutics – Phase II Clinical Pipeline, 2010 42
• Table 7: Angina Pectoris Therapeutics – Phase I Clinical Pipeline, 2010 43
• Table 8: Angina Pectoris Therapeutics – Preclinical Pipeline, 2010 43
• Table 9: List of Discontinued Drugs for Angina Pectoris, 2010 44
• Table 10: Cardium Therapeutics, Inc. –Cardiovascular Pipeline Products, 2010 49
• Table 11: Bayer Healthcare AG –Cardiovascular Pipeline Products, 2010 52
• Table 12: Solvay Pharmaceuticals –Cardiovascular Pipeline Products, 2010 54
• Table 13: Atherogenics, Inc. Laboratories–Cardiovascular Pipeline Products, 2010 56
• Table 14: Cytokinetics, Inc.–Cardiovascular Pipeline Products, 2010 58
• Table 15: Arca Biopharma, Inc.–Cardiovascular Pipeline Products, 2010 59
• Table 16: Anthera Pharmaceuticals, Inc. Cardiovascular Pipeline Products, 2010 61
• Table 17: Lacer S.A Laboratories–Cardiovascular Pipeline Products, 2010 62
• Table 18: Circ Pharma–Cardiovascular Pipeline Products, 2010 64

1.2 List of Figures

• Figure 1: Global Angina Pectoris Market Revenue ($m), 2001-2009 6
• Figure 2: Global Angina Pectoris Market Revenue ($m), 2009-2016 7
• Figure 3: Opportunity and Unmet Need in the Angina Disease Market, 2010 9
• Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Angina Pectoris, 2010 12
• Figure 5: Technology Trends Analytic Framework of the Angina Pectoris Pipeline, 2010 26
• Figure 6: Technology Trends Analytic Framework of the Angina Pectoris Pipeline – Description, 2010 27
• Figure 7: Angina Pectoris Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 40
• Figure 8: Angina Pectoris Pipeline by Phase of Clinical Development, 2010 41
• Figure 9: Implications for Future Market Competition in the Angina Pectoris Market, 2010 47
• Figure 10: Angina Pectoris Therapeutics Market – Clinical Pipeline by Company, 2010 48
• Figure 11: Methodology, 2010 67
• Figure 12: Market Forecasting Model, 2010 70

Other users found this report page using the following search terms: angina heart disease cad angina market pectoris pipeline drug drugs solvay pharma phase2anginadrugs cardiovascularpipelinedrugs

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.